SavedAdd your journal

Journals / Journal of Research in Veterinary Medicine / 2019 / Cilt: 38 - Sayı: 1

The Utilization Areas of Cabergoline in Veterinary Gynecology

Kudret YENILMEZ
Nihal EREN
Pages
77–81
Publication Date
2019-07-18
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Cabergoline is a potent dopamine agonist and a synthetic ergot derivative, and it acts by inhibiting prolactin secretion from the pituitary

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Cabergoline is a potent dopamine agonist and a synthetic ergot derivative, and it acts by inhibiting prolactin secretion from the pituitary
📊
Key Findings & Data:Cabergoline is a potent dopamine agonist and a synthetic ergot derivative, and it acts by inhibiting prolactin secretion from the pituitary
💡
Conclusion & Impact:Cabergoline is a potent dopamine agonist and a synthetic ergot derivative, and it acts by inhibiting prolactin secretion from the pituitary
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Cabergoline · veterinary · gynaecology

Abstract

Cabergoline is a potent dopamine agonist and a synthetic ergot derivative, and it acts by inhibiting prolactin secretion from the pituitary

🔖

Cite This Article

YENILMEZ, K., EREN, N. (2019). The Utilization Areas of Cabergoline in Veterinary Gynecology. Journal of Research in Veterinary Medicine, Cilt: 38 - Sayı: 1, 77–81. https://ajindex.com/articles/778594

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (12)

  1. Colao A, Di Sarno A, Sarnacchiaro F, et al. Prolactinomas resistant to standard dopamine agonists respond to chronic cabergoline treatment. Int J Clin Endocrinol Metab. 1997; 82(3): 876-883
  2. Kaya S. Üremeyi Etkileyen Hormonlar In: Kaya S, ed. Veteriner Farmakoloji 4. Baskı Ankara Medisan Yayınevi 2007:81 3- Balçık O, 2007. Hiperprolaktinomide kabergolinin düşük doz ve kısa dönem idame tedavisinin etkinliğinin araştırılması. T.C. Saglık Bakanlıgı Dr. Lütfi Kırdar Kartal Egitim ve Arastırma Hastanesi 2. Kadın Hastalıkları ve Dogum Klinigi Uzmanlık Tezi 4- Colao A, Di Sarno A, Landi ML, et al. Macroprolactinoma shrinkage during cabergoline treatment is greater in naive patients than in patients pretreated with other dopamine agonists: a prospective study in 110 patients. Int J Clin Endocrinol Metab. 2000; 85(6):2247-2252
  3. Jochle W, Arbeiter K, Post K, Ballabio R. Effects on pseudo-pregnancy, pregnancy and interoestrous intervals of pharmacological suppression of prolactin secretion in female dogs and cats. J Reprod Fertil. 1989; 39:199-207 6- Verstegen JP, Onclin K, Silva LD, et al. Abortion induction in the cat using prostaglandin F2 alpha and a new anti-prolactinic agent, cabergoline. J Reprod Fertil. 1993; ( 47): 411-417
  4. Eguchi K, Kawamoto K, Uozumi T, et al. Effect of Cabergoline, a Dopamine Agonist, on Estrogen-Induced Rat Pituitary Tumors. Endocr J. 1995; 42(3): 413-420
  5. Concannon PW. Reproductive cycles of the domestic bitch. Anim Reprod Sci. 2011; 124(3): 200-210
  6. Nak D, Nak Y, Simsek G. Comparison of the use of cabergoline and gonadotrophin to treat primary and secondary anoestrus in bitches. Aust Vet J. 2012; 90(5): 194- 196
  7. Kalkan C, Horoz H, 2001. Pubertas ve Seksüel Sikluslar In: Alaçam E, ed. Evcil Hayvanlarda Doğum ve İnfertilite 3. Baskı Ankara Medisan Yayınevi 2001: 23-40 11- Rains CP, Bryson HM, Fitton A. Cabergoline. Drugs. 1995; 49(2): 255-279
  8. Günay A, 2015. Köpeklerde Östrus Siklusunu Uyarma Yöntemleri. Acta Vet Eurasia. 2015; 41(2): 238-244
  9. Kutzler MA. Estrus induction and synchronization in canids and felids. Theriogenology. 2007; 68(3):354- 374
  10. Gobello C, Castex G, Corrada Y. Use of cabergoline to treat primary and secondary anestrus in dogs. JAVMA. 2002; 220(11): 1653-1654
  11. Verstegen JP, Onclin K, Silva LDM, et al. Effect of stage of anestrus on the induction of estrus by the dopamine agonist cabergoline in dogs. Theriogenology. 1999; 51(3): 597-611
  12. Rota A, Mollo A, Marinelli L, et al. E